Scholarlink

<p>Atopic dermatitis (AD) is one of the most frequent conditions treated by dermatologists. The therapeutic options for moderate-to-severe AD are rapidly expanding with the introduction of biologics and Janus kinase inhibitors (JAKis). There are currently three oral JAKis approved for the treatment of AD, namely abrocitinib, baricitinib and upadacitinib. Although JAKis are rapidly effective for treating AD and its symptoms, they require careful patient selection and monitoring due to a side-effect profile which includes an increased risk of major adverse cardiovascular events (MACE) and malignancies, especially in patients with pre-existing risk factors. The aim of this article is to provide practical recommendations on how to prescribe, monitor and manage potential adverse reactions of systemic JAKis for AD, and to assist dermatologists in navigating various scenarios that can be encountered in clinic.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mastering the Use of Systemic JAK Inhibitors for Atopic Dermatitis: A Dermatologist's Practical Guide

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Ahmad Jalili,
  • Sofia Labbouz,
  • Melinda Gooderham,
  • Michael Ziv,
  • Roni P. Dodiuk-Gad

摘要

Atopic dermatitis (AD) is one of the most frequent conditions treated by dermatologists. The therapeutic options for moderate-to-severe AD are rapidly expanding with the introduction of biologics and Janus kinase inhibitors (JAKis). There are currently three oral JAKis approved for the treatment of AD, namely abrocitinib, baricitinib and upadacitinib. Although JAKis are rapidly effective for treating AD and its symptoms, they require careful patient selection and monitoring due to a side-effect profile which includes an increased risk of major adverse cardiovascular events (MACE) and malignancies, especially in patients with pre-existing risk factors. The aim of this article is to provide practical recommendations on how to prescribe, monitor and manage potential adverse reactions of systemic JAKis for AD, and to assist dermatologists in navigating various scenarios that can be encountered in clinic.